BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO)

Historical Holders from Q2 2019 to Q1 2025

Symbol
BBIO on Nasdaq
CUSIP
10806X102
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
189M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
177M
Holdings value
$4.85B
% of all portfolios
0.01%
Grand Portfolio weight change
+0%
Number of holders
264
Number of buys
136
Number of sells
-110
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VIKING GLOBAL INVESTORS LP 11.7% $762M 22.1M VIKING GLOBAL INVESTORS LP Jan 31, 2025
KKR Genetic Disorder L.P. 10.1% $666M 19.3M KKR Genetic Disorder L.P. Mar 5, 2025
Kumar Neil 5.41% $362M 10.5M NEIL KUMAR Dec 31, 2024

Institutional Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 1.49M $51.4M +$38.4M $34.57 24
2024 Q4 177M $4.85B +$120M $27.44 264
2024 Q3 171M $4.36B -$97.3M $25.46 256
2024 Q2 175M $4.43B +$85.7M $25.33 252
2024 Q1 170M $5.27B +$130M $30.92 245
2023 Q4 165M $6.65B +$98.9M $40.37 242
2023 Q3 161M $4.23B +$311M $26.37 216
2023 Q2 149M $2.56B -$53.8M $17.20 194
2023 Q1 152M $2.52B +$153M $16.58 208
2022 Q4 145M $1.1B -$14.6M $7.62 173
2022 Q3 145M $1.44B +$49M $9.94 167
2022 Q2 138M $1.25B -$25.4M $9.08 149
2022 Q1 141M $1.43B -$30.3M $10.15 163
2021 Q4 141M $2.36B -$120M $16.68 177
2021 Q3 140M $6.56B -$165M $46.87 206
2021 Q2 143M $8.69B +$97.1M $60.96 196
2021 Q1 141M $8.68B +$1.24B $61.60 196
2020 Q4 121M $8.58B +$180M $71.11 158
2020 Q3 118M $4.39B +$21.7M $37.52 124
2020 Q2 117M $3.82B +$146M $32.61 113
2020 Q1 113M $3.27B +$163M $29.00 92
2019 Q4 99.9M $3.5B +$148M $35.05 83
2019 Q3 103M $2.22B +$110M $21.47 73
2019 Q2 99.9M $2.7B +$2.7B $26.97 60